EU Withdraws Levamisole Drugs Over Brain Disorder Risk
- European regulators are recommending the withdrawal of levamisole-containing medications from the market, citing concerns over a rare but serious neurological side effect.
- Levamisole is an anthelmintic medication, meaning it’s used to treat parasitic worm infections.
- Leukoencephalopathy is a rare but severe condition affecting the brain’s white matter.
European regulators are recommending the withdrawal of levamisole-containing medications from the market, citing concerns over a rare but serious neurological side effect. The move, announced by the European Medicines Agency (EMA) on , follows a comprehensive safety review that determined the risks associated with the drug now outweigh its benefits.
What is Levamisole?
Levamisole is an anthelmintic medication, meaning it’s used to treat parasitic worm infections. Specifically, it has been used for ascariasis and hookworm infections, and is administered orally. It’s also used as a dewormer in cattle. While effective against these parasites, the EMA’s review highlighted a significant safety concern: leukoencephalopathy.
Leukoencephalopathy: A Serious Neurological Condition
Leukoencephalopathy is a rare but severe condition affecting the brain’s white matter. The EMA confirmed that levamisole is linked to this potentially life-threatening side effect. Symptoms can appear anywhere from a day to several months after treatment, even after a single dose, making early detection challenging. The condition impacts the brain’s ability to function properly, and while some benefit has been observed with treatments like intravenous corticosteroids and plasma exchange, there are no established strategies to effectively reduce the risk of developing leukoencephalopathy.
The EMA Review Process
The EMA’s decision stems from a thorough review conducted by the Pharmacovigilance Risk Assessment Committee (PRAC). This committee analyzed data from EU safety monitoring systems, published medical literature, and individual case reports. A 2022 analysis of 30 Russian cases of levamisole-induced leukoencephalopathy further informed the review. The PRAC concluded that, given the severity of leukoencephalopathy and the lack of ways to mitigate the risk or identify susceptible patients, the benefit-risk balance for levamisole is no longer favorable.
Which Medications are Affected?
The withdrawal applies to all levamisole-containing medications authorized for human use within the European Union. This includes antelmintic medications specifically designed to treat intestinal worm infections, systemic antiparasitic medications used for milder infections, and products containing levamisole as a single active ingredient. These medications are typically prescribed for relatively common, non-life-threatening parasitic infestations for which alternative treatments are available.
What Happens Next?
With the PRAC’s recommendation, levamisole-containing medications will be removed from the EU market. The EMA has also issued a communication to physicians, pharmacists, and other healthcare professionals alerting them to the risk of leukoencephalopathy and the decision to withdraw the medications. This communication will be disseminated through the marketing authorization holders and published in national health registries across EU member states.
Levamisole Beyond Medical Use
It’s important to note that levamisole has a history of misuse. It is frequently used as a cutting agent in illegally produced cocaine, posing additional health risks to individuals who use these substances. This illicit use is separate from the EMA’s review, which focuses solely on the safety of legally prescribed medications.
Implications for Patients
Patients currently taking levamisole-containing medications should consult with their healthcare provider to discuss alternative treatment options. The EMA’s decision aims to protect public health by removing a medication with an unacceptable risk profile. While levamisole has been a useful tool in treating parasitic infections, the availability of safer alternatives makes its continued use unwarranted.
The EMA’s action underscores the importance of ongoing safety monitoring of medications, even those that have been used for many years. As new information emerges about potential risks, regulatory agencies like the EMA play a crucial role in protecting patients by making informed decisions about drug availability and use.